CardioVascular and Interventional Radiology

, Volume 40, Issue 10, pp 1535–1544 | Cite as

Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter

  • Gunnar TepeEmail author
  • Özlem Gögebakan
  • Ulf Redlich
  • Jörg Tautenhahn
  • Jens Ricke
  • Zuhir Halloul
  • Dirk-Roelfs Meyer
  • Matthias Waliszewski
  • Beatrix Schnorr
  • Thomas Zeller
  • Stefan Müller-Hülsbeck
  • Ilka Ott
  • Thomas Albrecht
Clinical Investigation



Based on a novel paclitaxel–resveratrol drug matrix, the safety and efficacy to inhibit intimal hyperplasia were studied in symptomatic claudicants with morphologically challenging lesions.


The treatment of peripheral artery occlusive disease (PAOD) with percutaneous transluminal angioplasty is limited by occurrence of vessel recoil and neointimal hyperplasia. Drug-coated balloons (DCB) deliver drugs to the arterial wall to potentially reduce the restenosis rate. A number of paclitaxel-coated balloon technologies are available to treat peripheral lesions.


In this randomized controlled trial, a total of 153 patients with symptomatic PAOD in femoro-popliteal lesions were randomized either to DCB or plain old balloon angioplasty (POBA).


The mean lesion length was 13.2 ± 10.4 cm with target lesion total occlusions in 26.1% of all patients (40/153). The primary endpoint of in-lesion late lumen loss (LLL) at 6 months was significantly reduced in the DCB group as compared to the POBA group (0.35 mm CI [0.19; 0.79 mm] vs. 0.72 mm CI [0.68; 1.22 mm], p = 0.006). At 12 months, the TLR rate in the DCB group was significantly lower as compared to the POBA group (17.8 vs. 37.7% p = 0.008). The censored walking distance increase suggests a benefit for patients who underwent DCB angioplasty as compared to the standard POBA treatment (12 months 165 ± 105 vs. 94 ± 136 m, p = 0.012).


The use of paclitaxel–resveratrol-matrix-coated peripheral balloon angioplasty as compared to POBA was associated with significantly reduced in-lesion LLL and reduced TLR rates. identifier NCT01970579.


Drug-coated balloon catheter Peripheral artery occlusive disease Femoro-popliteal lesions 



The authors wish to thank Dr. Bettina Kelsch, Dr. Maren Kutschera and Dr. Ines Gemeinhardt at InnoRa Berlin, Germany, for their respective efforts in conducting and monitoring this trial. We also wish to acknowledge Dr. Ralf Degenhardt at the Herzkreislaufzentrum Rotenburg, Germany, for his statistical support and Denny Herberger at Medical Scientific Affairs B.Braun, Berlin, for his logistic contributions. Finally, our thanks are extended to the members of our critical event committee consisting of Prof. Vorwerk (Klinikum Ingolstadt), Prof. Gebauer (Charité Berlin) and Dr. Fiedler (Harzklinikum Wernigerode).


All study participants received funding from B.Braun per included patient within a milestone-based system.

Compliance with Ethical Standards

Conflict of interest

GT and TA have lectured and received research grants from B.Braun. MW is a full-time employee of Medical Scientific Affairs department of B.Braun Melsungen AG.


  1. 1.
    Diehm C, Allenberg JR, Pittrow D, et al. German epidemiological trial on ankle brachial index study group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053–61.CrossRefPubMedGoogle Scholar
  2. 2.
    Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Schillinger M, Minar E. Claudication: treatment options for femoropopliteal disease. Prog Cardiovasc Dis. 2011;54(1):41–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Albrecht T, Speck U, Baier C, et al. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol. 2007;42(8):579–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.CrossRefPubMedGoogle Scholar
  6. 6.
    Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.CrossRefPubMedGoogle Scholar
  7. 7.
    Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Laird JR, Schneider PA, Tepe G, et al. IN.PACT SFA trial investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–38.CrossRefPubMedGoogle Scholar
  9. 9.
    Rosenfield K, Jaff MR, White CJ, et al. LEVANT 2 investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145-53. Cardiol. 2015;66(21):2329-38.Google Scholar
  10. 10.
    Katsanos K, Kitrou P, Spiliopoulos S, Diamantopoulos A, Karnabatidis D. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23(6):851–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, Kastrati A, Byrne RA. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9(16):1731–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23(2):356–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11(1):13–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Schroeder H, Meyer DR, Lux B, et al. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86(2):278–86.CrossRefPubMedGoogle Scholar
  16. 16.
    Scheinert D, Schulte KL, Zeller T, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Jia X, Zhang J, Zhuang B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the acoart I trial. JACC Cardiovasc Interv. 2016;9(18):1941–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1 Pt A):102–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017

Authors and Affiliations

  • Gunnar Tepe
    • 1
    Email author
  • Özlem Gögebakan
    • 2
  • Ulf Redlich
    • 3
  • Jörg Tautenhahn
    • 3
  • Jens Ricke
    • 4
  • Zuhir Halloul
    • 4
  • Dirk-Roelfs Meyer
    • 5
  • Matthias Waliszewski
    • 6
  • Beatrix Schnorr
    • 7
  • Thomas Zeller
    • 8
  • Stefan Müller-Hülsbeck
    • 9
  • Ilka Ott
    • 10
  • Thomas Albrecht
    • 2
  1. 1.Department of RadiologyRoMed Klinikum RosenheimRosenheimGermany
  2. 2.Department of Radiology and Interventional RadiologyVivantes Hospital Berlin NeuköllnBerlinGermany
  3. 3.Departments of Radiology and Vascular SurgeryKlinikum MagdeburgMagdeburgGermany
  4. 4.Departments of Radiology and Vascular SurgeryUniversity Hospital MagdeburgMagdeburgGermany
  5. 5.Department of Diagnostic and Interventional RadiologyHubertus HospitalBerlinGermany
  6. 6.Medical Scientific AffairsBerlinGermany
  7. 7.Charité UniversitätsmedizinBerlinGermany
  8. 8.University Heart Center Bad KrozingenBad KrozingenGermany
  9. 9.Diakonissenanstalt zu FlensburgFlensburgGermany
  10. 10.Heart Center MunichMunichGermany

Personalised recommendations